BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25081390)

  • 1. NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
    Chen JL; Dawoodji A; Tarlton A; Gnjatic S; Tajar A; Karydis I; Browning J; Pratap S; Verfaille C; Venhaus RR; Pan L; Altman DG; Cebon JS; Old LL; Nathan P; Ottensmeier C; Middleton M; Cerundolo V
    Int J Cancer; 2015 Mar; 136(6):E590-601. PubMed ID: 25081390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.
    Odunsi K; Matsuzaki J; Karbach J; Neumann A; Mhawech-Fauceglia P; Miller A; Beck A; Morrison CD; Ritter G; Godoy H; Lele S; duPont N; Edwards R; Shrikant P; Old LJ; Gnjatic S; Jäger E
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5797-802. PubMed ID: 22454499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
    Cebon JS; Gore M; Thompson JF; Davis ID; McArthur GA; Walpole E; Smithers M; Cerundolo V; Dunbar PR; MacGregor D; Fisher C; Millward M; Nathan P; Findlay MPN; Hersey P; Evans TRJ; Ottensmeier CH; Marsden J; Dalgleish AG; Corrie PG; Maria M; Brimble M; Williams G; Winkler S; Jackson HM; Endo-Munoz L; Tutuka CSA; Venhaus R; Old LJ; Haack D; Maraskovsky E; Behren A; Chen W
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
    Mischo A; Bubel N; Cebon JS; Samaras P; Petrausch U; Stenner-Liewen F; Schaefer NG; Kubuschok B; Renner C; Wadle A
    Int J Oncol; 2011 Jul; 39(1):287-94. PubMed ID: 21573493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
    Davis ID; Chen W; Jackson H; Parente P; Shackleton M; Hopkins W; Chen Q; Dimopoulos N; Luke T; Murphy R; Scott AM; Maraskovsky E; McArthur G; MacGregor D; Sturrock S; Tai TY; Green S; Cuthbertson A; Maher D; Miloradovic L; Mitchell SV; Ritter G; Jungbluth AA; Chen YT; Gnjatic S; Hoffman EW; Old LJ; Cebon JS
    Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10697-702. PubMed ID: 15252201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant.
    Chen Q; Jackson H; Parente P; Luke T; Rizkalla M; Tai TY; Zhu HC; Mifsud NA; Dimopoulos N; Masterman KA; Hopkins W; Goldie H; Maraskovsky E; Green S; Miloradovic L; McCluskey J; Old LJ; Davis ID; Cebon J; Chen W
    Proc Natl Acad Sci U S A; 2004 Jun; 101(25):9363-8. PubMed ID: 15197261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
    Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
    Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.
    Jäger E; Karbach J; Gnjatic S; Neumann A; Bender A; Valmori D; Ayyoub M; Ritter E; Ritter G; Jäger D; Panicali D; Hoffman E; Pan L; Oettgen H; Old LJ; Knuth A
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14453-8. PubMed ID: 16984998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
    Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
    J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.
    Nicholaou T; Chen W; Davis ID; Jackson HM; Dimopoulos N; Barrow C; Browning J; Macgregor D; Williams D; Hopkins W; Maraskovsky E; Venhaus R; Pan L; Hoffman EW; Old LJ; Cebon J
    Cancer Immunol Immunother; 2011 Nov; 60(11):1625-37. PubMed ID: 21698545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
    Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
    Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
    Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
    Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers.
    Drane D; Maraskovsky E; Gibson R; Mitchell S; Barnden M; Moskwa A; Shaw D; Gervase B; Coates S; Houghton M; Basser R
    Hum Vaccin; 2009 Mar; 5(3):151-7. PubMed ID: 19246990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
    Uenaka A; Wada H; Isobe M; Saika T; Tsuji K; Sato E; Sato S; Noguchi Y; Kawabata R; Yasuda T; Doki Y; Kumon H; Iwatsuki K; Shiku H; Monden M; Jungbluth AA; Ritter G; Murphy R; Hoffman E; Old LJ; Nakayama E
    Cancer Immun; 2007 Apr; 7():9. PubMed ID: 17441676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
    Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
    Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
    Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
    Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.